For instance, studies have shown that approximately 25% of adults with diabetes reported rationing insulin in the previous ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

An analysis from IQVIA found that between 2017 and 2021 the U.S. spent $260 billion on originator biologics, 2 the reference ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

The Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in ...

Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with ...

BENGALURU/HYDERABAD (Reuters) -Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European ...

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has reported that the FDA has approved the biosimilar treatment ...